Organon & Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
The PennZone/10310866

Trending...
PHILADELPHIA, July 17, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") (NYSE: OGN) on behalf of purchasers of Organon securities between November 3, 2022 through April 30, 2025, inclusive (the "Class Period").

Investor Deadline: Investors who purchased or acquired Organon securities during the Class Period may, no later than JULY 22, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

According to the lawsuit, defendants failed to disclose that Organon faced a higher risk of loss of exclusivity and price erosion as to Nexplanon. Thus, Nexplanon sales growth was not as strong as defendants represented and would not reach $1 billion by the end of fiscal year 2025. As a result, Organon was likely not on track to achieve the $1 billion milestone payment from Merck & Co. on its Nexplanon sales.

More on The PennZone
On May 1, 2025, investors learned the truth when Organon announced that management reset the Company's dividend payout from $0.28 per share to $0.02 per share. Organon's senior management explained that the Company had "reset our capital allocation priorities to accelerate progress towards deleveraging" and that "returning capital to shareholders is right now, less of a priority."

On this news, the price of Organon stock declined $3.48 per share – approximately 27% – from a closing price of $12.93 per share on April 30, 2025 to a close of $9.45 per share on May 1, 2025.

To learn your rights or for more information, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865.

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

More on The PennZone
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contact:

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]

Caitlin Adorni
Berger Montague
(267) 764-4865
[email protected]

SOURCE Berger Montague
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on The PennZone